In order to evaluate the in vivo anti-cancer effects of HDAC3 inhibition, we employed a CCA tumor xenograft model and found that HDAC3 knockdown cells also showed a low proliferative capacity and tumorigenicity compared to their counterparts (Figure 6A-6C). This evidence concerns the gene HDAC3 and cholangiocarcinoma.